CYP19A1 and breast cancer: Anastrozole, ZN 1033, (Arimidex®) and letrozole, CGS 20267, (Femara®) are selective aromatase inhibitors, available for clinical use in North America, Europe and other parts of the world for treatment of postmenopausal breast cancer.